Synthesis and biological activity of novel N-cycloalkyl-(cycloalkylaryl)-2- [(3-R-2-oxo-2H-[1,2,4]triazino[2,3-c]quinazoline-6-yl)thio]acetamides

European Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2011, Pages 6066-6074

  Berest, Galyna G ^a   Voskoboynik, Olexii Yu ^a   Kovalenko, Sergiy I ^a   Antypenko, Olexii M ^a   Nosulenko, Inna S ^a   Katsev, Andrii M ^b   Shandrovskaya, Olena S ^b  

^a ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

^b V I VERNADSKY CRIMEAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Antibacterial; Anticancer; Bioluminescence inhibition; N cycloalkyl (cycloalkylaryl) 2 (3 R 2 oxo 2H 1,2,4 triazino 2,3 c quina zoline 6 yl)thio acetamides

Indexed keywords

ACETAMIDE DERIVATIVE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; N (3 ETHYLBICYCLO[2.2.1]HEPT 2 YL) 2 (3 METHYL 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL THIO)ACETAMIDE; N (3 ETHYLBICYCLO[2.2.1]HEPT 2 YL) 2 [3 (4 METHOXYPHENYL) 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL THIO]ACETAMIDE; N (3 ETHYLBICYCLO[2.2.1]HEPT 2 YL) 2 [3 (4 METHYLPHENYL) 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL THIO]ACETAMIDE; N 1 ADAMANTYL 2 [(3 METHYL 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N 1 ADAMANTYL 2 [(3 PHENYL 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL)THIO]ACETAMIDE; N 1 ADAMANTYL 2 [3 (4 METHYLPHENYL) 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL]THIO]ACETAMIDE; N [4 (1 ADAMANTYL)PHENYL] 2 (3 METHYL 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL THIO)ACETAMIDE; N [4 (1 ADAMANTYL)PHENYL] 2 (3 PHENYL 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL THIO)ACETAMIDE; N [4 (1 ADAMANTYL)PHENYL] 2 [3 (4 METHOXYPHENYL) 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL THIO]ACETAMIDE; N [4 (1 ADAMANTYL)PHENYL] 2 [3 (4 METHYLPHENYL) 2 OXO 2H [1,2,4]TRIAZINO[2,3 C]QUINAZOLIN 6 YL THIO]ACETAMIDE; NYSTATIN; OXACILLIN; QUINAZOLINE DERIVATIVE; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ALKYLATION; AMINOLYSIS; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIOLUMINESCENCE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PHOTOBACTERIUM LEIOGNATHI; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL INFECTIONS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; QUINAZOLINES;

EID: 80955137528     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.10.022     Document Type: Article

References (42)

1. M. Kidwai, R. Venkataramanan, R. Mohan, and P. Sapra Chemotherapy and heterocyclic compounds Curr. Med. Chem. 9 2002 1209 1228
2. C. Carmi, A. Cavazzoni, S. Vezzosi, F. Bordi, F. Vacondio, G. Silva, S. Rivara, A. Lodola, R.R. Alfieri, S.L. Monica, M. Galetti, A. Ardizzoni, P.G. Petronini, and M. Mor Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion J. Med. Chem. 53 5 2010 2038 2050
3. V.G. Pawar, M.L. Sos, H.B. Rode, M. Rabiller, S. Heynck, W.A.L. van Otterlo, R.K. Thomas, and D. Rauh Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor J. Med. Chem. 53 7 2010 2892 2901
4. A. Antonello, A. Tarozzi, F. Morroni, A. Cavalli, M. Rosini, P. Hrelia, M.L. Bolognesi, and C. Melchiorre Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects J. Med. Chem. 49 23 2006 6642 6645 (Pubitemid 44749729)
5. S.R. Klutchko, Hairong Zhou, R.T. Winters, P. Tran Tuan, A.J. Bridges, I.W. Althaus, D.M. Amato, W.L. Elliott, P.A. Ellis, M.A. Meade, B.J. Roberts, D.W. Fry, A.J. Gonzales, P.J. Harvey, J.M. Nelson, V. Sherwood, Hyo-Kyung Han, G. Pace, J.B. Smaill, W.A. Denny, and H.D. Hollis Showalter Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4- d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors J. Med. Chem. 49 4 2006 1475 1485 (Pubitemid 43271900)
6. V.M. Sharma, K.V.A. Seshu, V.C. Sekhar, S. Madan, B. Vishnu, P.A. Babu, C.V. Krishna, J. Sreenu, V.R. Krishna, A. Venkateswarlu, S. Rajagopal, R. Ajaykumar, and T.S. Kumar Synthesis and biological evaluation of [4-(2-phenylethenesulfonylmethyl)phenyl]-quinazolin-4-yl-amines as orally active anti-cancer agents Bioorg. Med. Chem. Lett. 14 2004 67 71 (Pubitemid 38010196)
7. A. Vema, S.K. Panigrahi, G. Rambabu, B. Gopalakrishnan, J.A.R.P. Sarma, and G.R. Desiraju Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies Bioorg. Med. Chem. 11 2003 4643 4653 (Pubitemid 37194269)
8. J.B. Smaill, H.D. Hollis Showalter, H. Zhou, A.J. Bridges, D.J. McNamara, D.W. Fry, J.M. Nelson, V. Sherwood, P.W. Vincent, B.J. Roberts, W.L. Elliott, and W.A. Denny Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor J. Med. Chem. 44 3 2001 429 440 (Pubitemid 32113588)
9. W.A. Denny The 4-anilinoquinazoline class of inhibitors of the erbB famyli of receptors tyrosine kinases IL. Farmaco. 56 2001 51 56 (Pubitemid 32372583)
10. T. Hwei-Ru, N. Mamuya, B.D. Johnson, M.F. Reich, B.C. Gruber, Fei Ye, R. Nilakantan, Ru Shen, C. Discafani, R. DeBlanc, R. Davis, F.E. Koehn, L.M. Greenberger, Yu-Fen Wang, and A. Wissner 6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity J. Med. Chem. 44 17 2001 2719 2734 (Pubitemid 32879714)
11. G.W. Rewcastle, W.A. Denny, and H.D.H. Showalter Synthesis of 4-(phenylamino)-pyrimidine derivatives as ATP-competitive protein kinase inhibitors with potential for cancer chemotherapy Curr. Org. Chem. 4 2000 679 706 (Pubitemid 30611645)
12. J.B. Smaill, G.W. Rewcastle, J.A. Loo, K.D. Greis, O.H. Chan, E.L. Reyner, E. Lipka, H.D. Hollis Showalter, P.W. Vincent, W.L. Elliott, and W.A. Denny Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions J. Med. Chem. 43 7 2000 1380 1397 (Pubitemid 30212579)
13. Y.D. Wang, K. Miller, D.H. Boschelli, F. Ye, B. Wu, M.B. Floyd, D.W. Powell, A. Wissner, J.M. Weber, and F. Boschelli Inhibitors of Src tyrosine kinase: the preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines Bioorg. Med. Chem. Lett. 10 2000 2477 2480
14. R. Ovadekova, S. Jantova, V. Theiszova, and J. Labuda Cytotoxicity and detection of damage to DNA by 3-(5-nitro-2-thienyl)-9-chloro-5-mopholin-4-yl-[1, 2,4]triazolo[4,3-c]quinazoline on human cancer cell line HeLa Biomed. Pap. Med. Fac. 149 2 2005 455 459 Univ. Palacky Olomouc Czech. Repub.
15. C. Lamazzi, S. Leonce, B. Pfeiffer, P. Renard, G. Guillaumet, C.W. Rees, and T. Besson Expeditious synthesis and cytotoxic activity of new cyanoindolo[3,2-c]quinolines and benzimidazolo[1,2-c]quinazolines Bioorg. Med. Chem. Lett. 10 2000 2183 2185
16. R. Baruah, K. Dasu, B. Vaitilingam, P. Mamnoor, P.P. Venkata, S. Rajagopal, and K.R. Yeleswarapu Synthesis and cytotoxic activity of novel quinazolino-β-carboline-5-ones derivatives Bioorg. Med. Chem. 12 2004 1991 1994 (Pubitemid 38471692)
17. M.A.E. Shaban, M.A.M. Taha, and A.Z. Nasr Synthesis of 1,2,4-triazino[4,3-c]quinazolines and 4-(pyrazol-1-yl)quinazolines Heterocycl. Commun. 4 5 1998 473 478
18. E.S.H. El Ashry, N. Rashed, A. Mousaad, and E. Ramadan Condensed 1,2,4-Triazines: II. Fused to heterocycles with six- and seven-membered rings and fused to two heterocyclic rings Adv. Heterocycl. Chem. 61 1994 267 270
19. S.I. Kovalenko, I.F. Belenichev, V.V. Galitsa, and O.V. Krivoshey Synthesis of 2-(3,4-dihydro-3-oxo-2H-[1,2,4]triazino[4,3-c]quinazolin-4-yl) acetic acid derivatives as potential antioxidants in nitrosative stress model Pharmacia 58 2 2010 145 157
20. S.G. Abdel-Hamide Synthesis of some new heterocyclic systems bearing 2-phenyl-6-iodo-4(3H)-quinazolinon-3-yl moiety as antibacteral agents J. Indian Chem. Soc. 74 1997 613 618 (Pubitemid 127488769)
21. E. Bansal, T. Ram, S. Sharma, M. Tyagi, A.P. Rani, K. Bajaj, R. Tyagi, B. Goel, V.K. Srivastava, J.N. Guru, and A. Kumar Thiazolydinyl- triazinoquinazolines as potent anti-inflammatory agents Indian J. Chem. Sect. B. 40 4 2001 307 312
22. D.L. Trepanier, S. Sunder, and W.H. Braun 1,2,4-Triazino[4,3-c]- and [2,3-c]quinazolines J. Heterocycl. Chem. 11 5 1974 747 750
23. D.L. Trepanier, and S. Sunder 1,2,4-Triazino[4,3-c]- and [2,3-cquinazolines J. Heterocycl. Chem. 12 2 1975 321 326
24. G. Doleschall, and K. Lempert 1,2,4-triazines and condensed derivatives - XVI: 1-oxo-1,2-dihydro- and 1-oxo-1,2,6,7-tetrahydro[1,2,4]triazino[1,6-c]- quinazolin-5-ium salts. Synthesis and some reactions Tetrahedron 32 1976 1735 1740
25. H.A. llimony, H.M. El-Shaaer, S.G. Abdel-Hamide, S.A. Abdel-Aziz, and R.M. Abdel-Rahman Synthesis and reactions of some new 1,2,4- triazinoquinazolinone derivatives Indian J. Chem. Sect. B. 35 10 1996 1026 1030 (Pubitemid 126463393)
26. S.S. Ibrahim, A.M. Abdel-Halim, Y. Gabr, S. El-Edfawy, and R.M. Abdel-Rahman Synthesis and biological evaluation of some new fused quinazoline derivatives J. Chem. Res. (M) 5 1997 1041 1063
27. H.M.F. Madkour Reactivity of 4H-3,1-benzoxazin-4-ones towards nitrogen and carbon nucleophilic reagents: applications to the synthesis of new heterocycles ARKIVOC i 2004 36 54 (Pubitemid 38783185)
28. S.I. Kovalenko, A.V. Karpenko, O.V. Krivoshey, S.V. Shishkina, and O.V. Shishkin Novel method for the synthesis of [1,2,4]triazino[4,3-c]quinazoline system Synth. Commun. 37 2007 3719 3727 (Pubitemid 47613515)
29. O.V. Karpenko, S.I. Kovalenko, O.O. Chekotylo, and S.V. Shyshkyna A new one-step synthesis of [1,2,4]triazino[2,3-c]quinazolines HETEROCYCLES 71 3 2007 619 626
30. A.V. Karpenko, S.I. Kovalenko, and O.V. Shishkin Synthesis of spiro-fused (C5)-pyrazolino-(C6)-triazinones, a new heterocyclic system Tetrahedron 65 31 2009 5964 5972
31. G.G. Berest, A. Yu. Voskoboynic, S.I. Kovalenko, R.S. Sinyak, I.V. Omelchenko, O.V. Shishkin, E.Z. Komarovska-Porokhnyavets, and V.P. Novikov An Efficient Synthesis of 3-R-6-thio-6,7-dihydro-2-[1,2,4]triazino[2,3-c]- quinazoline-2-ones and its Derivatives, Antimicrobial and Antifungal Activity J. Org. Pharm. Chem. 8 3 2010 42 52 http://www.pharm.kharkiv.edu/files/ %D0%96%D0%9E%D0%A4%D0%A5-%E2%84%963-2010-%D1%81.42-51.pdf
32. 1-thio-6,7-dihydro-2-[1,2,4]triazino[2,3-] quinazolin-2-nes and their derivatives Official Bulletin "Promyslova Vlasnist" (Industrial Property) 11 2010 3.56 3.57
33. J. Liu, D. Obando, V. Liao, T. Lifa, and R. Codd The many faces of the adamantyl group in drug design Eur. J. Med. Chem. 46 2011 1949 1963
34. E.I. Bagriy Features of structure and properties of adamantans Science 1989 5 57 oscow
35. G.W. Smith, and H.D. Williams Some reactions of adamantane and adamantane derivatives J. Org. Chem. 26 7 1961 2207 2212 10.1021/jo01351a011
36. L.N. Antipenko, A.V. Karpenko, S.I. Kovalenko, A.M. Katsev, E. Komarovska-Porokhnyavets, V. Novikov, and A. Chekotilo Synthesis of new 2-thio-[1,2,4]triazolo[1,5-c]quinazoline derivatives and its antimicrobial activity Chem. Pharm. Bull. 57 2009 580 585
37. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - 9th Edition, Wayne, PA, Clinical and Laboratory Standards Institute, CLSI M2-A9.
38. http://dtp.nci.nih.gov.
39. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, and A. Vaigro-Wolff Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Nat. Cancer Inst. 83 11 1991 757 766
40. M.R. Boyd, and K.D. Paull Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen Drug Dev. Res. 34 1995 91 109
41. M.R. Boyd The NCI in vitro anticancer drug discovery screen; concept, implementation and operation B.A. Teicher, Cancer Drug Discovery and Development vol. 2 1997 Humana Press 23 43
42. R.H. Shoemaker, D.A. Scudiero, and G. Melillo Application of high-throughput, molecular-targeted screening to anticancer drug discovery Curr. Top. Med. Chem. 2 3 2002 229 246